",
"amzAssAppIframe": "",
"hasBeenTweeted": true,
"numberOfTimesTweeted": 0,
"numTimesSharedFb": 0,
"isBreakingNews": false,
"isLink": false,
"linkUrl": null,
"iexDividendDto": [],
"subjects": []
},
"createDate": "2022-08-08T22:26:53.5697306Z",
"updateDate": null
},
{
"dto": {
"id": 0,
"title": "",
"reportId": null,
"report": null,
"content": "![](\"https://s3-us-west-2.amazonaws.com/surge-diligence/images/4938/1206/2018120117_32_19CelgeneCorporationandAcceleronPharmaAnnounceResultsofthePhase3BELIEVE.png\")
",
"isBlog": false,
"order": 0,
"user": null,
"createDate": "0001-01-01T00:00:00Z",
"updateDate": "0001-01-01T00:00:00Z"
},
"id": 2969,
"name": null,
"order": 0,
"componentType": "TextEditor",
"report": {
"id": 4938,
"encodedId": null,
"title": "Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III",
"description": "Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018",
"slug": "Celgene-and-Acceleron",
"source": "http://investor.acceleronpharma.com",
"sourceUrl": "http://investor.acceleronpharma.com/news-releases/news-release-details/celgene-corporation-and-acceleron-pharma-announce-results-phase",
"createDate": "2018-12-02T01:40:44.05Z",
"updateDate": "2018-12-02T02:02:14.22Z",
"complete": null,
"cost": null,
"value": null,
"status": null,
"reportType": "News",
"isPosition": false,
"riskLevel": null,
"valuation": null,
"publicationStatus": "Published",
"publicationDate": "2018-12-02T01:41:55.847Z",
"numberOfRecords": 0,
"numberOfLetters": 0,
"openPrice": null,
"latestPrice": null,
"week52Low": null,
"week52High": null,
"purchasePrice": null,
"sellPrice": null,
"purchaseDate": null,
"sellDate": null,
"shares": null,
"age": null,
"ticker": "XLRN",
"bannerImageUrl": "http://investor.acceleronpharma.com/sites/g/files/knoqqb17841/themes/site/nir_pid1637/client/images/headerImg-investor-relations.jpg",
"thumbnailImageUrl": null,
"figi": "BBG004YTQJF4",
"iexQuoteDto": null,
"iexStockStatDto": null,
"iexFinancialsDto": null,
"iexEarningDto": null,
"positionDuration": null,
"dividendSchedule": null,
"amazonAssociatesIframe": "",
"amzAssAppIframe": "",
"hasBeenTweeted": true,
"numberOfTimesTweeted": 0,
"numTimesSharedFb": 0,
"isBreakingNews": false,
"isLink": false,
"linkUrl": null,
"iexDividendDto": [],
"subjects": []
},
"createDate": "2022-08-08T22:26:53.5697306Z",
"updateDate": null
},
{
"dto": {
"id": 0,
"title": "",
"reportId": null,
"report": null,
"content": "
",
"isBlog": false,
"order": 0,
"user": null,
"createDate": "0001-01-01T00:00:00Z",
"updateDate": "0001-01-01T00:00:00Z"
},
"id": 2970,
"name": null,
"order": 0,
"componentType": "TextEditor",
"report": {
"id": 4938,
"encodedId": null,
"title": "Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III",
"description": "Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018",
"slug": "Celgene-and-Acceleron",
"source": "http://investor.acceleronpharma.com",
"sourceUrl": "http://investor.acceleronpharma.com/news-releases/news-release-details/celgene-corporation-and-acceleron-pharma-announce-results-phase",
"createDate": "2018-12-02T01:40:44.05Z",
"updateDate": "2018-12-02T02:02:14.22Z",
"complete": null,
"cost": null,
"value": null,
"status": null,
"reportType": "News",
"isPosition": false,
"riskLevel": null,
"valuation": null,
"publicationStatus": "Published",
"publicationDate": "2018-12-02T01:41:55.847Z",
"numberOfRecords": 0,
"numberOfLetters": 0,
"openPrice": null,
"latestPrice": null,
"week52Low": null,
"week52High": null,
"purchasePrice": null,
"sellPrice": null,
"purchaseDate": null,
"sellDate": null,
"shares": null,
"age": null,
"ticker": "XLRN",
"bannerImageUrl": "http://investor.acceleronpharma.com/sites/g/files/knoqqb17841/themes/site/nir_pid1637/client/images/headerImg-investor-relations.jpg",
"thumbnailImageUrl": null,
"figi": "BBG004YTQJF4",
"iexQuoteDto": null,
"iexStockStatDto": null,
"iexFinancialsDto": null,
"iexEarningDto": null,
"positionDuration": null,
"dividendSchedule": null,
"amazonAssociatesIframe": "",
"amzAssAppIframe": "",
"hasBeenTweeted": true,
"numberOfTimesTweeted": 0,
"numTimesSharedFb": 0,
"isBreakingNews": false,
"isLink": false,
"linkUrl": null,
"iexDividendDto": [],
"subjects": []
},
"createDate": "2022-08-08T22:26:53.5697306Z",
"updateDate": null
}
],
"reportDetail": null,
"authorDto": {
"uuid": null,
"userName": "blueequitynow",
"firstName": "Blue",
"lastName": "Equity",
"isPaidUser": false,
"s3ProfileImageRelativePath": null,
"profileUrl": "https://s3-us-west-2.amazonaws.com/surge-diligence/profile-image/512e622d-869d-4818-bdfd-1e700602de0a/512x512bb.jpg",
"isPremiumMember": false,
"customerStripeId": null,
"currency": null,
"twitter": null,
"kindleEmail": null,
"createDate": null,
"defaultFirm": null,
"defaultFund": null,
"isLicensed": false,
"role": null,
"company": null,
"isEmployee": false,
"isUpcomingEarnings": false,
"isNotificationLikeEnabled": false,
"isNotificationMentionEnabled": false,
"isNotificationReplyEnabled": false,
"stockTwitsAuthToken": null,
"twitterToken": null,
"twitterTokenSecret": null,
"stock": null,
"companyLogo": null
}
}
![](\"https://s3-us-west-2.amazonaws.com/surge-diligence/images/4938/1207/2018120117_32_19CelgeneCorporationandAcceleronPharmaAnnounceResultsofthePhase3BELIEVE.png\")